Drugs / NPT 2042
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07222878 | Sep → Nov 2025 | Alzheimer disease, epilepsy | NeuroPro Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05503511 | Oct 2022 → Mar 2023 | Alzheimer disease, epilepsy | NeuroPro Therapeutics, Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06525649 Comparator | Aug 2024 → Jun 2025 | photosensitive epilepsy | NeuroPro Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06769659 Comparator | Mar 2025 → Aug 2026 overdue | epilepsy syndrome, generalized epilepsy | NeuroPro Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPT 2042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07222878 ↗ |
| Route | Oral | “NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects” NCT05503511 ↗ |